Gene therapy for vein graft disease

Current Cardiology Reports

Volumn 3, Issue 1, 2001, Pages 22-28

  Cable, David G ^a   Schaff, Hartzell V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; GENE THERAPY; GRAFT OCCLUSION; HUMAN; HYPERPLASIA; INTIMA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REPORTER GENE; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ENDOTHELIUM, VASCULAR; GENE THERAPY; GENES, REPORTER; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; TUNICA INTIMA;

EID: 0035227493     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0006-0     Document Type: Article

References (43)

1. Nwasokwa ON: Coronary artery bypass graft disease. AnnInt Med 1995, 123:528-545.
2. Motwani JG, Topol EJ: Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998, 97:916-931.
3. Chesebro JH, Clements IP, Fuster V, et al.: A platelet inhibitor drug trial in coronary artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein graft patency. N Engl J Med 1982, 307:73-78.
4. Chesebro JH, Fuster V, Elveback LR, et al.: Effect of dipyridamole and aspirin on late vein graft patency after coronary bypass operations. N Engl J Med 1984, 310:209-214.
5. Lytle BW, Loop FD, Cosgrove DM, et al.: Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 1985, 89:248-258.
6. Goldman S, Copeland J, Moritz T, et al.: Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1989, 80:1190-1197.
7. Limet R, David JL, Magotteaux P, et al.: Prevention of aortacoronary bypass graft occlusion: beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg 1987, 94:773-783.
8. Tsutsui M, Chen AFY, O'Brien T, et al.: Adventitial expression of recombinant eNOS gene restores NO production in arteries without endothelium. Arterioscler Thromb Vasc Biol 1998, 18:1231-1241.
9. Cable DG, O'Brien T, Schaff HV, Pompili VJ: Recombinant endothelial nitric oxide synthase-transduced human saphenous veins: gene therapy to augment nitric oxide production in bypass conduits. Circulation 1997, 96:II 173-II 178.
10. Imagawa H, Taniguchi K, Takahashi I: Gene transfer with hemagglutinating virus of Japan-liposome into human saphenous vein graft; preventive way against vein graft disease [abstract]. Circulation 1996, 94(suppl I):I-477.
11. Kupfer JM, Ruan XM, Liu G, et al.: High-efficiency gene transfer to autologous rabbit jugular vein grafts using adenovirustransferrin/ plylysine-DNA complexes. Hum Gene Ther 1994, 5:1437-1443.
12. Channon KM, Fulton GJ, Gray JL, et al.: Efficient adenoviral gene transfer to early venous bypass grafts: comparison with native vessels. Cardiovasc Res 1997, 35:505-513.
13. Chikada M, Jones M: Study of gene delivery in a rabbit vein graft model: improvements of the efficiency of gene transfer into vein grafts. Japan J Thorac Cardiovasc Surg 1999, 47:204-209.
14. Feldman L, Steg G, Zheng L, et al.: Low efficiency of percutanous adnovirus-mediated arterial gene transfer in the atherosclerotic rabbit. J Clin Invest 1995, 95:2662-2671.
15. Rekhter MD, Simari RD, Work CW, et al.: Gene transfer into normal and atherosclerotic human blood vessels. Circ Res 1998, 82:1243-1252.
16. Chikada M, Jones M: Study of gene delivery in a rabbit vein graft model: improvement of the efficiency of gene transfer into vein grafts. J Jap Thorac Cardiovasc Surg 1999, 47:204-209.
17. Champion HC, Bivalacqua TJ, D'Souza FM, et al.: Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo: effect on agonist-induced and flow-mediated vascular responses. Circ Res 1999, 84:1422-1432.
18. Chiu CK, O'Brien T, Katusic ZS, et al.: Gene transfer to saphenous vein coronary bypass conduits [abstract]. FASE B 2000, 14:A688.
19. Rade JJ, Schulick AH, Virmani R, Dichek DA: Local adenoviralmediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med 1996, 2:293-298.
20. Rade JJ, Cheung M, Miyamoto S, Dichek DA: Retroviral vectormediated expression of hirudin by human vascular endothelial cells: implications for the design of retroviral vectors expressing biologically active proteins. Gene Ther 1999, 6:385-392.
21. Waugh JM, Yuksel E, Li J, et al.: Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res 1999, 84:84-92.
22. Dunn PF, Newman KD, Jones M, et al.: Seeding of vascular grafts with genetically modified endothelial cells: secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo. Circulation 1996, 93:1439-1446.
23. Zoldhelyi P, McNatt J, Xu XM, et al.: Prevention of arterial thrombosis by adenovirus-mediated transfer of cylcooxygenase gen. Circulation 1996, 93:10-17.
24. Cable DG, Caccitolo JA, Caplice N, et al.: The role of gene therapy for intimal hyperplasia of bypass grafts. Circulation 1999, 100:II392-II396.
25. Matsumoto T, Komori K, Yonemitsu Y, et al.: Hemagglutinating virus of Japan-liposome-mediated gene transfer of endothelial cell nitric oxide synthase inhibits intimal hyperplasia of canine vein grafts under conditions of poor runoff. J Vasc Surg 1998, 27:135-144.
26. Kibbe MR, Nie S, Yoneyama T, et al.: Optimization of ex vivo inducible nitric oxide synthase gene transfer to vein grafts. Surgery 1999, 126:323-329.
27. Schwartz LB, Moawad J, Svensson EC, et al.: Adenoviralmediated gene transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts. J Vasc Surg 1999, 29:874-883.
28. Chen SJ, Wilson JM, Muller DWM: Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation 1994, 89:1922-1928.
29. Huynh TTT, Iaccarino G, Davies MG, et al.: Adenoviral-mediated inhibition of Gbg signaling limits the hyperplastic response in experimental vein grafts. Surgery 1998, 124:177-186.
30. Davies MG, Huynh TTT, Fulton GJ, et al.: G-protein signaling and vein graft intimal hyperplasia: reduction of intimal hyperplasia in vein grafts by a Gbg inhibitor suggests a major role of G protein signaling in lesion development. Arterioscler Thromb Vasc Biol 1998, 18:1275-1280.
31. George SJ, Johnson JL, Angelini GD, et al.: Adenovirusmediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous veins. Human Gene Therapy 1998, 9:867-877.
32. George SJ, Baker GD, Angelini GD, Newby AC: Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther 1998, 5:1552-1560.
33. George SJ, Lloyd CT, Angelini GD, et al.: Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000, 101:296-304.
34. Bai H, Morishita R, Kida I, et al.: Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. Hum Gene Ther 1998, 5:761-769.
35. Hanna AK, Duran WN, Leconte I, et al.: Adenoviral-mediated expression of antisense RNA to basic fibroblast growth factor reduces tangential stress in arterialized vein grafts. J Vasc Surg 2000, 31:770-780.
36. Hanna AK, Fox JC, Neschis DG, et al.: Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J Vasc Surg 1997, 25:320-325.
37. Neschis DG, Safford SD, Hanna AK, et al.: Antisense basic fibroblast growth factor gene transfer reduces early intimal thickening in a rabbit femoral artery balloon injury model. J Vasc Surg 1998, 27:126-134.
38. Mann MJ, Gibbons GH, Kernoff RS, et al.: Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA 1995, 92:4502-4506.
39. Mann MJ, Gibbons GH, Tsao PS, et al.: Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest 1997, 99:1295-1301.
40. Mann MJ, Whittemore AD, Donaldson MC, et al.: Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomized, controlled trial. Lancet 1999, 354:1493-1498.
41. Clesham GJ: Gene therapy made difficult. Heart 1998, 80:313-314.
42. Morishita R: Lessons from human arteries: how to design a gene therapy strategy for treatment of cardiovascular disease. Circ Res 1998, 82:1349-1351.
43. Smith AE: Gene therapy-where are we? Lancet 1999, 354(suppl I):1-4.